ENDOMETRIUM AND HORMONAL REPLACEMENT THERAPY
Abstract
BACKGROUND Estrogen induces endometrial stimulation and increases the risk for endometrial hyperplasia and endometrial cancer. Added progestin diminishes endometrial stimulation.The risk for endometrial hyperplasia with hormonal replacement therapy (HRT) dependsof the type of formulation. Unopposed estrogen increases the risk of abnormal uterinebleeding, endometrial hyperplasia and carcinoma in a dose and time dependent manner.When progestin was added for 10 or more days, no endometrial hyperplasia has beenseen with sequential HRT. No increased risk for endometrial hyperplasia has been foundwith continuous combined regimens. During the first year of HRT irregular bleeding andspotting was more likely in continuous combined therapy than in sequential therapy.Howerever, during the second year of the therapy it was more likely under sequentialregimens. CONCLUSIONS Only women after hysterectomy can use unopposed estrogenDownloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
